ZA200402557B - Glucagon-like peptides (GLP-1) and treatment of respiratory distress. - Google Patents

Glucagon-like peptides (GLP-1) and treatment of respiratory distress.

Info

Publication number: ZA200402557B
Authority: ZA; South Africa
Prior art keywords: glp; glucagon; peptides; treatment; respiratory distress
Prior art date: 2001-10-01

Application number

ZA200402557A

Other languages

English (en)

Inventor

Suad Efendic

Joseph Anthony Jakubowski

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-01

Filing date

2004-03-31

Publication date

2005-05-09

2004-03-31 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2005-05-09 Publication of ZA200402557B publication Critical patent/ZA200402557B/xx

Links

DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 title 2
108010088406 Glucagon-Like Peptides Proteins 0.000 title 2
206010038687 Respiratory distress Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

ZA200402557A 2001-10-01 2004-03-31 Glucagon-like peptides (GLP-1) and treatment of respiratory distress. ZA200402557B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US32633001P	2001-10-01	2001-10-01

Publications (1)

Publication Number	Publication Date
ZA200402557B true ZA200402557B (en)	2005-05-09

Family

ID=23271764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200402557A ZA200402557B (en)	2001-10-01	2004-03-31	Glucagon-like peptides (GLP-1) and treatment of respiratory distress.

Country Status (19)

Country	Link
US (2)	US20040235726A1 (xx)
EP (1)	EP1443952A4 (xx)
JP (1)	JP2005523877A (xx)
KR (1)	KR20040040482A (xx)
CN (1)	CN1561224A (xx)
BR (1)	BR0212620A (xx)
CA (1)	CA2462543A1 (xx)
CZ (1)	CZ2004441A3 (xx)
EA (1)	EA200400501A1 (xx)
EC (1)	ECSP045044A (xx)
HR (1)	HRP20040258A2 (xx)
HU (1)	HUP0600437A2 (xx)
IL (1)	IL160631A0 (xx)
MX (1)	MXPA04002996A (xx)
NO (1)	NO20041351L (xx)
PL (1)	PL373846A1 (xx)
SK (1)	SK1432004A3 (xx)
WO (1)	WO2003028626A2 (xx)
ZA (1)	ZA200402557B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003532691A (ja)	2000-05-05	2003-11-05	ノボノルディスクアクティーゼルスカブ	重症疾患神経障害
US20030199445A1 (en)	2002-02-07	2003-10-23	Knudsen Lotte Bjerre	Use of GLP-1 compound for treatment of critically ill patients
AU2003203146A1 (en) *	2002-02-07	2003-09-02	Novo Nordisk A/S	Use of glp-1 compound for treatment of critically ill patients
WO2003072143A1 (en) *	2002-02-27	2003-09-04	Pharmain, Ltd.	Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20050260259A1 (en) *	2004-04-23	2005-11-24	Bolotin Elijah M	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
CA2551039C (en)	2003-12-16	2013-01-29	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R	Analogues of glp-1
TWI364292B (en)	2005-06-30	2012-05-21	Ipsen Pharma Sas	Glp-1 pharmaceutical compositions
AU2006330610B2 (en)	2005-12-19	2012-08-16	Pharmain Corporation	Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
MX2008013304A (es)	2006-04-20	2008-10-27	Amgen Inc	Compuestos de peptido 1 tipo glucagon.
JP2010043001A (ja) *	2006-11-09	2010-02-25	Sanwa Kagaku Kenkyusho Co Ltd	Ｇｌｐ−１誘導体とその用途
US7960336B2 (en)	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en)	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
EP2340049B1 (en)	2008-09-12	2015-11-11	Novo Nordisk A/S	Method of acylating a peptide or protein
WO2010054326A2 (en)	2008-11-07	2010-05-14	The General Hospital Corporation	C-terminal fragments of glucagon-like peptide-1 (glp-1)
EP2216042A1 (en)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP-1 analogues pharmaceutical compositions
DE102009024229B3 (de) *	2009-06-08	2010-10-14	Salzsieder, Eckhard, Dipl.-Phys., Dr. rer.nat.	Indikationseinrichtung zur automatisierten Bestimmung des individuellen Inkretin-Sensitivitäts-Indexes eines Probanden
JP2013530993A (ja)	2010-07-02	2013-08-01	アンジオケムインコーポレーテッド	治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
US9040481B2 (en)	2010-11-02	2015-05-26	The General Hospital Corporation	Methods for treating steatotic disease
EP2729157B1 (en)	2011-07-06	2019-01-16	The General Hospital Corporation	A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
ES2810153T3 (es) *	2012-03-01	2021-03-08	Novo Nordisk As	Profármacos de GLP-1
US20230218556A1 (en) *	2020-05-01	2023-07-13	Irazu Bio	Method for treating respiratory viral infections comprising administration of fatty acid compositions
CN116847868A (zh) *	2021-01-29	2023-10-03	韩美药品株式会社	用于预防或治疗肺部疾病的包括gip衍生物或其长效共轭物的药学组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6006753A (en) *	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
MY155270A (en) *	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6271241B1 (en) *	1999-04-02	2001-08-07	Neurogen Corporation	Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors

2002
- 2002-09-19 SK SK143-2004A patent/SK1432004A3/sk not_active Application Discontinuation
- 2002-09-19 BR BR0212620-6A patent/BR0212620A/pt not_active IP Right Cessation
- 2002-09-19 EP EP02761559A patent/EP1443952A4/en not_active Withdrawn
- 2002-09-19 CZ CZ2004441A patent/CZ2004441A3/cs unknown
- 2002-09-19 IL IL16063102A patent/IL160631A0/xx unknown
- 2002-09-19 CN CNA028194535A patent/CN1561224A/zh active Pending
- 2002-09-19 EA EA200400501A patent/EA200400501A1/ru unknown
- 2002-09-19 JP JP2003531963A patent/JP2005523877A/ja active Pending
- 2002-09-19 WO PCT/US2002/028123 patent/WO2003028626A2/en active Application Filing
- 2002-09-19 US US10/488,670 patent/US20040235726A1/en not_active Abandoned
- 2002-09-19 CA CA002462543A patent/CA2462543A1/en not_active Abandoned
- 2002-09-19 KR KR10-2004-7004767A patent/KR20040040482A/ko not_active Application Discontinuation
- 2002-09-19 HU HU0600437A patent/HUP0600437A2/hu unknown
- 2002-09-19 MX MXPA04002996A patent/MXPA04002996A/es not_active Application Discontinuation
- 2002-09-19 PL PL02373846A patent/PL373846A1/xx not_active Application Discontinuation
2004
- 2004-03-17 HR HRP20040258 patent/HRP20040258A2/xx not_active Application Discontinuation
- 2004-03-31 NO NO20041351A patent/NO20041351L/no unknown
- 2004-03-31 ZA ZA200402557A patent/ZA200402557B/xx unknown
- 2004-04-01 EC EC2004005044A patent/ECSP045044A/es unknown
2007
- 2007-08-22 US US11/842,967 patent/US20080032932A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2003028626A2 (en)	2003-04-10
CA2462543A1 (en)	2003-04-10
PL373846A1 (en)	2005-09-19
BR0212620A (pt)	2005-09-20
CN1561224A (zh)	2005-01-05
NO20041351D0 (no)	2004-03-31
EP1443952A4 (en)	2005-09-07
ECSP045044A (es)	2004-04-28
EA200400501A1 (ru)	2005-06-30
WO2003028626A3 (en)	2003-10-09
MXPA04002996A (es)	2004-07-15
US20080032932A1 (en)	2008-02-07
CZ2004441A3 (cs)	2004-11-10
KR20040040482A (ko)	2004-05-12
HUP0600437A2 (en)	2006-09-28
SK1432004A3 (sk)	2005-03-04
US20040235726A1 (en)	2004-11-25
EP1443952A2 (en)	2004-08-11
HRP20040258A2 (en)	2004-12-31
NO20041351L (no)	2004-06-30
IL160631A0 (en)	2004-07-25
JP2005523877A (ja)	2005-08-11

Publication	Publication Date	Title
ZA200402557B (en)	2005-05-09	Glucagon-like peptides (GLP-1) and treatment of respiratory distress.
EP1448222A4 (en)	2006-05-17	BIPHASIC MIXTURES OF GLP-1 AND INSULIN
HUP0501192A3 (en)	2006-06-28	Glucagon-like peptide-1 analogs
EP1363602A4 (en)	2006-01-11	LOCAL ANESTHESIA, AND METHOD OF USE
ZA200204416B (en)	2004-06-30	Carbon dioxide enhancement of inhalation therapy.
PT1360202E (pt)	2008-09-01	Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
ZA200404144B (en)	2006-03-29	Treatment of asthma and respiratory disease by means of electrical neuro-receptive waveforms.
AU2002213925A1 (en)	2002-03-26	Use of glp-1 and flp-2 peptides for treatment of bone disorders
MXPA03006936A (es)	2003-11-18	Tratamiento de diabetes mellitus.
ZA200207211B (en)	2003-07-14	Disposable breathing mask.
AP2003002918A0 (en)	2003-12-31	Pulmonary administration of chemically modified insulin.
EP1578719A4 (en)	2006-07-05	P-HYDROXY-MILNACIPRAN STEREOISOMERS AND METHODS OF USING THE SAME
AU2003234529A8 (en)	2003-12-12	Glp-1 gene delivery for the treatment of type 2 diabetes
AU2003231911A1 (en)	2003-12-31	Emergency medical kit, respiratory pump, and face mask particularly useful therein
GB0004531D0 (en)	2000-04-19	The treatment of respiratory diseases
AU2003232148A8 (en)	2003-12-02	A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
LU91070B1 (en)	2004-04-15	Treatment and diagnosis of insulin resistant states
GB2383397B (en)	2005-10-12	Breathing apparatus
GB2381459B (en)	2006-05-31	Breathing/resuscitation apparatus including nebuliser
EP1406921A4 (en)	2004-08-25	HYPOGLYCAEMIC PEPTIDES AND METHOD FOR USE THEREOF
AU151952S (en)	2003-06-05	Nasal mask
GB0022844D0 (en)	2000-11-01	Use of GLP-1 and GLP-2 peptides
GB0029920D0 (en)	2001-01-24	Use of glp-1 and glp-2 peptides
AU2002365933A8 (en)	2007-08-30	Production of recombinant therapeutic bioscavengers against chemical and biological agents
GB0111553D0 (en)	2001-07-04	Hormone replacement treatment therapy